Here, authors show that Smad3 acetylation via HDAC6 inhibition reverses Duchenne muscular dystrophy-like symptoms in the mdx mouse model, suggesting a potential therapeutic target for the disorder. The gene discussed is HDAC6; the disease is Duchenne muscular dystrophy.